Potential Analysis of Human DNA Vaccines Market to Cross $9,337 Million by 2030
The global potential analysis of human DNA vaccines market is expected to account for $3,762 million by 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030. Key opportunities for market expansion include the high need for vaccines for immunization & prevention of infectious diseases.
Vaccines used currently are composed of killed pathogen or live attenuated viruses, whereas DNA vaccines consist of the DNA sequence of the antigen, which is administered in humans to stimulate an immune response. This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent, and the relative ease of large-scale manufacture.
Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/2309
The major players profiled in the global potential analysis of human DNA vaccines market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.
Key Findings of the Potential Analysis of Human DNA Vaccines Market:
North America is expected to dominate the market in 2020, and is projected to grow at the highest CAGR during the forecast period. Europe is the second largest potential market, and is expected to grow at a CAGR of 9.0%.
Make an Enquiry for Purchase Report @ https://www.alliedmarketresearch.com/purchase-enquiry/2309
Table of Content
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.3. TOP INVESTMENT POCKETS
3.4. HUMAN DNA VACCINES-KEY FACTS
3.5. REGULATION OF VACCINES BY FDA
3.6. CLINICAL TRIALS
3.7. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.8. MARKET OPPORTUNITIES